Patents by Inventor Stuart T. Nichol

Stuart T. Nichol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10064933
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 4, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Publication number: 20180002675
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: August 28, 2017
    Publication date: January 4, 2018
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 9795665
    Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 24, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Patent number: 9790473
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: October 17, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 9687542
    Abstract: Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRPRVF) vaccine candidate. VRPRVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPRVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRPRVF, methods of producing VRPRVF, and method of using VRPRVF for immunization against RVF virus infection.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: June 27, 2017
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Kimberly A. Dodd, Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol
  • Publication number: 20160331827
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 17, 2016
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health and Human Servic
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 9474796
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 25, 2016
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Colorado Seminary, which owns and operates the University of Denver
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Patent number: 9439935
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 13, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 9421250
    Abstract: Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: August 23, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Laura K. McMullan, Cynthia Goldsmith, Aubree Kelly, William L. Nicholson, Stuart T. Nichol
  • Publication number: 20150306202
    Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
    Type: Application
    Filed: August 13, 2013
    Publication date: October 29, 2015
    Inventors: Eric BERGERON, Scott Dusan PEGAN, Stuart T. NICHOL, Michelle Kay DEATON
  • Publication number: 20150218525
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 6, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Publication number: 20150196630
    Abstract: Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRPRVF) vaccine candidate. VRPRVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPRVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRPRVF, methods of producing VRPRVF, and method of using VRPRVF for immunization against RVF virus infection.
    Type: Application
    Filed: June 18, 2013
    Publication date: July 16, 2015
    Inventors: Kimberly A. Dodd, Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol
  • Publication number: 20150086577
    Abstract: Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 26, 2015
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Laura K. McMullan, Cynthia Goldsmith, Aubree Kelly, William L. Nicholson, Stuart T. Nichol
  • Publication number: 20140134207
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 15, 2014
    Applicant: The Government of the United States of America as represented by the Secretary of the Dept. of He
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 8673629
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: March 18, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Publication number: 20140050761
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 20, 2014
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Publication number: 20120251502
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: October 26, 2009
    Publication date: October 4, 2012
    Applicant: The Government of the US as Represented by the Secretary of the Dept. of health
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Publication number: 20110123567
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Application
    Filed: December 16, 2008
    Publication date: May 26, 2011
    Applicants: HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 6620913
    Abstract: The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 16, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart T. Nichol, Christina F. Spiropoulou, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 5945277
    Abstract: The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.
    Type: Grant
    Filed: May 30, 1996
    Date of Patent: August 31, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart T. Nichol, Christina F. Spiropoulou, Thomas G. Ksiazek, Pierre E. Rollin